Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 284, Issue 39, Pages 26322-26330Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M109.023192
Keywords
-
Categories
Funding
- Foundation for Scientific Research (Forschungskommission, University of Zurich)
- Hartmann Muller Foundation
- German Society for Clinical Chemistry and Laboratory Medicine (DGKL)
- EMDO Foundation
- European Commission [LSHM-CT-2006-037631]
Ask authors/readers for more resources
The enzyme serine palmitoyltransferase (SPT) catalyzes the rate-limiting step in the de novo synthesis of sphingolipids. Previously the mammalian SPT was described as a heterodimer composed of two subunits, SPTLC1 and SPTLC2. Recently we identified a novel third SPT subunit (SPTLC3). SPTLC3 shows about 68% identity to SPTLC2 and also includes a pyridoxal phosphate consensus motif. Here we report that the overexpression of SPTLC3 in HEK293 cells leads to the formation of two new sphingoid base metabolites, namely C-16-sphinganine and C-16-sphingosine. SPTLC3-expressing cells have higher in vitro SPT activities with lauryl-and myristoyl-CoA than SPTLC2-expressing cells, and SPTLC3 mRNA expression levels correlate closely with the C-16-sphinganine synthesis rates in various human and murine cell lines. Approximately 15% of the total sphingolipids in human plasma contain a C-16 backbone and are found in the high density and low density but not the very low density lipoprotein fraction. In conclusion, we show that the SPTLC3 subunit generates C-16-sphingoid bases and that sphingolipids with a C-16 backbone constitute a significant proportion of human plasma sphingolipids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available